Kilitch Drugs (India) logo

Kilitch Drugs (India) financials: balance sheet, profit and loss, cash flow

NSE: KILITCHBSE: 524500Pharmaceuticals & BiotechnologySmall Cap

Kilitch Drugs (India) Limited · Face value ₹10 · Listed May 1994 on BSE, Sep 2010 on NSE
Last close ₹214.97up ₹7.44 (3.59%)BSE ₹214.55

Share price at the NSE close on 28 Oct 2026. Previous close ₹207.53.

28 Oct: open ₹206.50, high ₹223.80, low ₹206.10

52-week range of traded prices to 28 Oct 2026
₹117.25Low, 30 Mar 2026₹267.90High, 7 Oct 2026
Market cap
₹752 Cr1,776th largest listed
P/E
25.01
P/B
2.69
Dividend yield
Nonein the last 12 months
ROE
12.5%
ROCE
8.9%
Debt to equity
0.32
Volume, NSE
72,07150.4% delivered

Kilitch Drugs (India)'s financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Kilitch Drugs (India) annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
29−11Mar 17515.2Mar 18823.89.5Mar 19530.813Mar 20693.815Mar 211146.220Mar 221408.322Mar 231541432Mar 241982549Mar 252353089Mar 26
Peak revenue ₹235 Cr, year to Mar 2026; lowest ₹29 Cr, year to Mar 2017A loss in 1 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin
15.9%−37.9%8.5%0.4%7.6%9.1%12.6%15.6%15.9%15.5%−37.9%10.1%4.6%1.6%5.5%5.4%5.9%8.8%12.6%12.5%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue235
  2. Materials and goods−126
  3. Employee costs−14
  4. Other expenses−58
  5. Operating profit37
  6. Depreciation−3.6
  7. Other income+11
  8. One-off items0.0
  9. Finance costs−5.6
  10. Profit before tax39
  11. Tax−9.2
  12. Net profit30

What the company owns

  • Plant, investments and other assets₹257 Cr
  • Receivables₹120 Cr
  • Current investments₹52 Cr
  • Cash and bank₹17 Cr
  • Inventory₹12 Cr

What pays for it: net worth and liabilities

  • Net worth₹277 Cr
  • Borrowings₹89 Cr
  • Owed to suppliers₹80 Cr
  • Other liabilities₹13 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Kilitch Drugs (India) quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 19 MayMar 2026Filed 15 MayJun 2026Twelve monthsFiled 13 Aug
Revenue from operations2951825369114140154198235237
––755363104122130167199201
Materials and goods bought1126482937657579105126125
Employee costs––56561210111416
Other expenses––221821323641515860
Operating profit before depreciation––705101824313736
Operating margin––8.5%0.4%7.6%9.1%12.6%15.6%15.9%15.5%15.3%
Materials, % of revenue––58.4%54.5%54.4%57.3%53.6%51.2%52.7%53.6%52.7%
Employee costs, % of revenue––6.4%10.7%7.6%5.4%8.4%6.5%5.7%6.1%6.6%
Other expenses, % of revenue––26.7%34.4%30.3%28.2%25.5%26.7%25.7%24.8%25.3%
Depreciation and amortisation102222243344
Operating profit after depreciation––5−2381421283332
Other income13443334111112
Finance costs––011156565
One-off items00000000000
Profit before tax−116925101219343939
−1151134610910
−1154146814253029
Other comprehensive income––−1−35206−1−11
Total comprehensive income––3−298819242830
Net margin−37.9%10.1%4.6%1.6%5.5%5.4%5.9%8.8%12.6%12.5%12.3%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2017 and Mar 2018: the statement does not state its finance costs, which operating profit is worked out from, so operating profit is not given.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 19 MayMar 2026Filed 15 May
123120129140151176200277
121118127139152176202280
Share capital1515151616161635
Reserves106103112124136160186245
Belonging to outside owners of subsidiaries2221−1−1−2−3
913152022324989
20227369696484122
0000002859
Total assets144143203210220240313458
7987123969394139236
655680114126146174222
Net debt−27−18−34−37−37−37−1020
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 19 MayMar 2026Filed 15 May
466301824
467212129
41−4−12−21−8−8
Receivables−9−19−12−12−23−38
Inventories2−13−2−114
Payables4723−2−122925
Other working capital1−605−30
Tax paid0−3−4−7−8−11
Interest paid−115656
Capital spending368400100
Free cash flow10−2−1018−76
−38−158−10−40−100
27−191382
Dividends paid000000
Shares bought back000000
Shares issued0300049
Net change in cash10−210−1−96
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Kilitch Drugs (India) dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 19 MayMar 2026Filed 15 May
−₹4.10₹1.95₹1.31₹0.28₹1.19₹2.37₹3.36₹4.59₹8.30₹8.91
As stated that year−₹8.20₹3.89₹2.61₹0.55₹2.37₹4.73₹6.71₹9.17₹16.60₹8.91
−₹4.10₹1.83₹1.31₹0.28₹1.19₹2.37₹3.36₹4.59₹8.30₹8.91
–₹0.25₹0.25–––––––
––₹39.42₹38.31₹41.02₹44.63₹48.64₹54.81₹62.90₹79.99
Dividend payout–13.3%20.0%–––––––
Shareholder yield––––0.0%−1.0%0.0%0.0%0.0%−11.2%
Market cap at the year end (₹ crore)60105299126124261217625583435
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Consolidated, years to March.Kilitch Drugs (India) PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 19 MayMar 2026Filed 15 May
Revenue growth36.5%78.0%61.7%−35.4%28.5%66.7%22.2%10.6%28.5%18.7%
Operating profit growth–––−97.2%2,540.0%99.7%69.4%37.5%30.3%16.3%
Net profit growth––−25.7%−78.0%347.3%65.0%33.3%63.9%83.7%18.3%
Earnings per share growth––−32.9%−78.9%330.9%99.6%41.9%36.7%81.0%7.3%
––3.2%0.7%3.0%5.5%7.2%8.9%14.1%12.5%
–––−2.5 pts2.3 pts2.5 pts1.7 pts1.7 pts5.2 pts−1.6 pts
From the net margin–––−2.1 pts1.7 pts0.6 pts0.9 pts1.9 pts3.8 pts−0.7 pts
From asset turnover–––−0.4 pts0.2 pts1.4 pts1.1 pts0.3 pts0.9 pts−2.0 pts
From borrowing–––0.0 pts0.5 pts0.5 pts−0.4 pts−0.5 pts0.6 pts1.1 pts
Return on capital employed––3.7%−1.4%2.2%4.9%8.1%10.0%11.3%9.0%
Cash conversion––––1,218.2%93.1%31.2%−1.1%70.3%81.2%
Interest cover––13.1–4.36.62.83.55.65.9
Debt to equity––0.080.100.110.150.150.180.250.32
Receivable days––86109122132142149156186
Inventory days––3670352810185333
Payable days––3389525239200118189230
Cash conversion cycle, days––8989−368−79−485020−11
Working capital days––77108−14425541059696
Asset turnover––0.570.370.400.550.650.670.720.61
Assets per rupee of net worth––1.191.201.411.551.481.401.461.60
Sales per rupee of plant––9.696.118.672.643.193.664.364.84
Capital spending to depreciation––––18.283.331.070.000.0027.46
Plant being built, % of plant in use––237.9%339.0%828.4%7.3%8.3%14.2%103.9%287.5%
Interest cover is left blank for the year to Mar 2020: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
7.8%
Cash from operations against operating profit
65.5%
Measure10 years5 years3 years
Revenue growth, yearly rate27.4%28.0%19.0%
Profit growth, yearly rate–52.4%42.4%
Return on equity, average–9.7%11.8%
Return on capital employed, average–8.7%10.1%
Operating margin, average–13.7%15.7%
Net margin, average2.9%9.1%11.3%
Asset turnover, average–0.640.67
Cash conversion cycle, days, average–−1320
Interest cover, average–4.95.0
Debt to equity, average–0.210.25

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations504124
Cash from investing−157−150−100
Cash from financing11110582
Capital spending112100100
Dividends paid000
Shares bought back000
Shares issued for cash514949
Borrowings raised746739
Borrowings repaid000

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––657552
Altman Z-scorePublished threshold 1.81–10.945.112.264.043.968.165.343.29
Beneish M-scorePublished threshold −1.78–––−3.12−1.73−2.20−2.08−1.71−1.86
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––−2.507.59−1.0310.1217.1327.51
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––2.970.290.430.61
Receivables growth less revenue growthOur threshold 0 percentage points––16.9616.0013.988.895.885.5623.08
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––57.45−63.73−35.96−73.3689.43251.45−45.36
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––−0.091.754.760.36−0.772.423.08
Assets under construction, years of additionsOur threshold 2 years of additions––13.3456.550.080.893.387.3020.61
Effective tax ratePublished threshold 17.16 per cent15.7055.4047.6126.4335.3731.0629.8627.6623.68
Tax charged less tax paid, % of profitOur threshold 10 percentage points––––8.99−4.99−6.493.09−3.59
A threshold marked as ours has no published figure; it is the line we read the check against.